Abstract

The FDA has approved a subcutaneously injected, extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine (Brixadi – Braeburn) for once-weekly or once-monthly treatment of moderate to severe opioid use disorder.

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Severe Opioid Use
  • Opioid Use
  • Agonist Receptor
  • Mu-opioid Agonist
  • Agonist Antagonist
    • + Show 5 more

Create a personalized feed of these topics

Get Started

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder
  • Journal of Clinical Psychopharmacology
  • Feb 1, 2016
Relevant
Not Relevant
Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review
  • Drug and Alcohol Dependence
  • Mar 1, 2020
Relevant
Not Relevant
Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department
  • Annals of Emergency Medicine
  • Sep 1, 2021
Relevant
Not Relevant
P40 Impact of a brief video to improve naloxone knowledge in adolescents and young adults with severe opioid use disorder
  • Nov 1, 2019
Relevant
Not Relevant
Cost‐effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial
  • Addiction
  • Mar 28, 2018
Relevant
Not Relevant
Evaluation of dynorphin and kappa-opioid receptor level in the human blood lymphocytes and plasma: Possible role as a biomarker in severe opioid use disorder
  • Drug and Alcohol Dependence
  • Dec 1, 2019
Relevant
Not Relevant
Opioid relapse and MOUD outcomes following civil commitment for opioid use
  • Journal of Substance Abuse Treatment
  • Nov 1, 2022
Relevant
Not Relevant
Case report: rapid inpatient methadone titration during pregnancy
  • Journal of Substance Use
  • Jul 16, 2021
Relevant
Not Relevant
Problematizing the DSM-5 criteria for opioid use disorder: A qualitative analysis
  • International Journal of Drug Policy
  • Apr 1, 2020
Relevant
Not Relevant
P33 Antibodies suggestive of immunity to hepatitis b and a are not detected in the majority of adolescents and young adults seeking medication-assisted treatment for opioid use disorder
  • Nov 1, 2019
Relevant
Not Relevant
HIV Treatment Initiation and Retention Among Individuals Initiated on Injectable Opioid Agonist Therapy for Severe Opioid Use Disorder: A Case Series
  • Journal of Addiction Medicine
  • Jan 31, 2020
Relevant
Not Relevant
Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series.
  • Journal of addiction medicine
  • Aug 4, 2020
Relevant
Not Relevant
Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
  • Journal of Clinical Psychopharmacology
  • May 1, 2020
Relevant
Not Relevant
Predictors of treatment allocation guesses in a randomized controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder
  • Addiction Research & Theory
  • Jul 4, 2017
Relevant
Not Relevant
Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment
  • Harm Reduction Journal
  • Jun 7, 2022
Relevant
Not Relevant
READ MORE FROM

The Medical letter on drugs and therapeutics

Sulbactam/durlobactam (Xacduro) for Acinetobacter pneumonia.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Shockwave therapy for erectile dysfunction.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
In brief: GI effects of GLP-1 receptor agonists.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Ritlecitinib (Litfulo) for severe alopecia areata.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Addendum.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Etrasimod (Velsipity) for ulcerative colitis.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
COVID-19 update: New Novavax vaccine formulation for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Correction.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
In brief: Empagliflozin (Jardiance) for chronic kidney disease.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Antiviral drugs for influenza for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant